Geftistar 250mg Tablet contains Gefitinib, a selective epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor used primarily in the treatment of non-small cell lung cancer (NSCLC). Gefitinib works by inhibiting the intracellular phosphorylation of tyrosine kinase associated with the EGFR, thereby blocking signal transduction pathways involved in the proliferation and survival of cancer cells. This targeted therapy is particularly effective in patients with tumors harboring specific EGFR mutations. Geftistar is indicated for the first-line treatment of locally advanced or metastatic NSCLC with activating EGFR mutations. The recommended dosage is 250 mg orally once daily, with or without food, and treatment should continue until disease progression or unacceptable toxicity occurs. Common adverse effects include rash, diarrhea, nausea, and elevated liver enzymes, with rare but serious risks such as interstitial lung disease and hepatotoxicity. Liver function tests and clinical monitoring are advised during therapy. Geftistar should be used under strict medical supervision, with dose adjustments or discontinuation considered based on patient tolerance and response. It is contraindicated in patients with known hypersensitivity to Gefitinib or any of its excipients. This medication represents a significant advancement in personalized cancer therapy, improving outcomes in selected NSCLC patients.